Catalyst Pharmaceuticals, Inc. Forecasted to Post Q1 2025 Earnings of $0.67 Per Share (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Investment analysts at Zacks Research upped their Q1 2025 earnings per share estimates for shares of Catalyst Pharmaceuticals in a research note issued on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of $0.67 for the quarter, up from their previous estimate of $0.64. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.69 EPS, Q3 2025 earnings at $0.67 EPS and FY2025 earnings at $2.70 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. The company had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%.

Several other analysts have also commented on the stock. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. Oppenheimer restated an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Citigroup started coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 14th. They set a “buy” rating and a $27.00 target price on the stock. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $26.43.

Catalyst Pharmaceuticals Trading Up 1.4 %

NASDAQ:CPRX opened at $14.89 on Friday. The company has a 50-day moving average price of $15.52 and a 200-day moving average price of $14.61. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of 24.07, a P/E/G ratio of 0.83 and a beta of 0.89. Catalyst Pharmaceuticals has a 12 month low of $11.09 and a 12 month high of $17.76.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth $31,000. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 72.9% in the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 819 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 306.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 3,829 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Catalyst Pharmaceuticals by 84.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 2,833 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Catalyst Pharmaceuticals in the third quarter worth approximately $123,000. 79.22% of the stock is owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $15.68, for a total value of $392,000.00. Following the transaction, the director now owns 348,874 shares in the company, valued at approximately $5,470,344.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 12.10% of the stock is owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.